Molecules, Vol. 27, Pages 4292: From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease
Molecules, Vol. 27, Pages 4292: From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease
Molecules doi: 10.3390/molecules27134292
Authors:
Matthias Göhl
Linlin Zhang
Haifa El Kilani
Xinyuanyuan Sun
Kaixuan Zhang
Mark Brönstrup
Rolf Hilgenfeld
The main protease (Mpro) of the betacoronavirus SARS-CoV-2 is an attractive target for the development of treatments for COVID-19. Structure-based design is a successful approach to discovering new inhibitors of the Mpro. Starting from crystal structures of the Mpro in complexes with the Hepatitis C virus NS3/4A protease inhibitors boceprevir and telaprevir, we optimized the potency of the alpha-ketoamide boceprevir against the Mpro by replacing its P1 cyclobutyl moiety by a γ-lactam as a glutamine surrogate. The resulting compound, MG-78, exhibited an IC50 of 13 nM versus the recombinant Mpro, and similar potency was observed for its P1′ N-methyl derivative MG-131. Crystal structures confirmed the validity of our design concept. In addition to SARS-CoV-2 Mpro inhibition, we also explored the activity of MG-78 against the Mpro of the alphacoronavirus HCoV NL63 and against enterovirus 3C proteases. The activities were good (0.33 µM, HCoV-NL63 Mpro), moderate (1.45 µM, Coxsackievirus 3Cpro), and relatively poor (6.7 µM, enterovirus A71 3Cpro), respectively. The structural basis for the diff...
Source: Molecules - Category: Chemistry Authors: Matthias G öhl Linlin Zhang Haifa El Kilani Xinyuanyuan Sun Kaixuan Zhang Mark Br önstrup Rolf Hilgenfeld Tags: Article Source Type: research
More News: Chemistry | Coronavirus | COVID-19 | Enterovirus | Hepatitis | Hepatitis C | Incivek | SARS